Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases

Radiology

Volumn 212, Issue 3, 1999, Pages 755-759

  Viala, Juliette ^a   Vanel, Daniel ^a   Meingan, Philippe ^a   Lartigau, Eric ^b   Carde, Patrice ^b   Renschler, Markus ^c  

^a Department of Radiology ^*  (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c PHARMACYCLICS INC   (United States)

Author keywords

Brain neoplasms, MR; Brain neoplasms, secondary; Brain neoplasms, therapeutic radiology; Contrast media; Texaphyrins

Indexed keywords

GADOLINIUM; GADOLINUM TEXAPHYRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG UPTAKE; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION; TREATMENT OUTCOME;

EID: 0032874534     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.212.3.r99se10755     Document Type: Article

References (7)

1. Young S, Qing F, Harriman A, et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 1996; 93:6610-6615.
2. Rosenthal DI, Nurenberg P, Becerra CR, et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999; 5:739-745.
3. Young SW, Sidhu MK, Qing F, et al. Preclinical evaluation of gadolinium (III) texaphyrin complex: a new paramagnetic contrast agent for magnetic resonance imaging. Invest Radiol 1994; 29:330-338.
4. Sessler JL, Hemmi G, Mody TD, Murai T, Burrell A, Young SA. Texaphyrins: synthesis and applications. Accounts Chem Res 1994; 27:43-50.
5. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Rad Oncol Biol Phys 1980; 6:1-9.
6. Urtasun R, Band P, Chapman JD, Feldstein ML, Mielke B, Fryer C. Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med 1976; 294:1364-1367.
7. Overgaard J, Sand Hansen H, Lindelov B, et al. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma: first report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol 1991; (suppl 1):143-149.